Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Aug;4(16):312.
doi: 10.21037/atm.2016.07.01.

Preventing or treating anti-EGFR related skin rash with antibiotics?

Fausto Petrelli  1 , Karen Borgonovo  1 , Sandro Barni  1
Affiliations
Editorial

Preventing or treating anti-EGFR related skin rash with antibiotics?

Fausto Petrelli et al. Ann Transl Med. 2016 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Comment on

References

    1. Brown J, Su Y, Nelleson D, et al. Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review. J Community Support Oncol 2016;14:21-8. 10.12788/jcso.0193 - DOI - PubMed
    1. Lichtenberger BM, Gerber PA, Holcmann M, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med 2013;5:199ra111. 10.1126/scitranslmed.3005886 - DOI - PubMed
    1. Mascia F, Mariani V, Girolomoni G, et al. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003;163:303-12. 10.1016/S0002-9440(10)63654-1 - DOI - PMC - PubMed
    1. Melosky B, Anderson H, Burkes RL, et al. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. J Clin Oncol 2016;34:810-5. 10.1200/JCO.2015.62.3918 - DOI - PubMed
    1. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:1351-7. 10.1200/JCO.2008.21.7828 - DOI - PubMed